Among these biomarkers, overexpressing PD-L1 expression on the one side is associated with worse prognosis in cancer patients [11] and on the other hand is considered a biologically plausible and targetable available biomarker in predicting the tumor response and survival prognosis. Here, CD274 is linked to neoplasm.